Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. McConville, BJ; Arvanitis, LA; Thyrum, PT; Yeh, C; Wilkinson, LA; Chaney, RO; Foster, KD; Sorter, MT; Friedman, LM; Brown, KL; Heubi, JE
   Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders
   JOURNAL OF CLINICAL PSYCHIATRY
   
   B.J. McConville et al., "Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders", J CLIN PSY, 61(4), 2000, pp. 252-260
2. McManus, DQ; Arvanitis, LA; Kowalcyk, BB
   Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
   JOURNAL OF CLINICAL PSYCHIATRY
   
   D.Q. McManus et al., "Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders", J CLIN PSY, 60(5), 1999, pp. 292-298
3. HONG WW; RAK IW; CIURYLA VT; WILSON AM; KYLSTRA JW; MELTZER HY; CARPENTER WT; LEHMAN A; ARVANITIS LA
   MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION
   Schizophrenia research
   
   W.W. Hong et al., "MEDICAL-CLAIMS DATABASES IN THE DESIGN OF A HEALTH-OUTCOMES COMPARISON OF QUETIAPINE (SEROQUEL) AND USUAL-CARE ANTIPSYCHOTIC MEDICATION", Schizophrenia research, 32(1), 1998, pp. 51-58
4. ARVANITIS LA; RAK IW
   THE LONG-TERM EFFICACY AND SAFETY OF SEROQUEL (QUETIAPINE)
   Schizophrenia research
   
   L.A. Arvanitis e I.W. Rak, "THE LONG-TERM EFFICACY AND SAFETY OF SEROQUEL (QUETIAPINE)", Schizophrenia research, 24(1-2), 1997, pp. 196-197
5. ARVANITIS LA; RAK IW
   EFFICACY, SAFETY AND TOLERABILITY OF SEROQUEL (QUETIAPINE) IN ELDERLYSUBJECTS WITH PSYCHOTIC DISORDERS
   Schizophrenia research
   
   L.A. Arvanitis e I.W. Rak, "EFFICACY, SAFETY AND TOLERABILITY OF SEROQUEL (QUETIAPINE) IN ELDERLYSUBJECTS WITH PSYCHOTIC DISORDERS", Schizophrenia research, 24(1-2), 1997, pp. 196-196
6. GOLDSTEIN JM; ARVANITIS LA
   SEROQUEL (QUETIAPINE), A PROMISING NEW ANTIPSYCHOTIC AGENT - OVERVIEWOF SAFETY AND TOLERABILITY
   Schizophrenia research
   
   J.M. Goldstein e L.A. Arvanitis, "SEROQUEL (QUETIAPINE), A PROMISING NEW ANTIPSYCHOTIC AGENT - OVERVIEWOF SAFETY AND TOLERABILITY", Schizophrenia research, 24(1-2), 1997, pp. 197-197
7. GOLDSTEIN JM; ARVANITIS LA
   SEROQUEL (QUETIAPINE) IS NOT ASSOCIATED WITH DOSE-RELATED EXTRAPYRAMIDAL SYMPTOMS - OVERVIEW OF CLINICAL-RESULTS
   Schizophrenia research
   
   J.M. Goldstein e L.A. Arvanitis, "SEROQUEL (QUETIAPINE) IS NOT ASSOCIATED WITH DOSE-RELATED EXTRAPYRAMIDAL SYMPTOMS - OVERVIEW OF CLINICAL-RESULTS", Schizophrenia research, 24(1-2), 1997, pp. 198-198
8. RAK IW; ARVANITIS LA
   OVERVIEW OF THE EFFICACY OF SEROQUEL (QUETIAPINE)
   Schizophrenia research
   
   I.W. Rak e L.A. Arvanitis, "OVERVIEW OF THE EFFICACY OF SEROQUEL (QUETIAPINE)", Schizophrenia research, 24(1-2), 1997, pp. 199-199
9. CANTILLON M; ARVANITIS LA
   CLINICAL-EXPERIENCE WITH QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC AGENT
   Psychopharmacology bulletin
   
   M. Cantillon e L.A. Arvanitis, "CLINICAL-EXPERIENCE WITH QUETIAPINE, AN ATYPICAL ANTIPSYCHOTIC AGENT", Psychopharmacology bulletin, 33(3), 1997, pp. 502-502
10. TARGUM SD; ARVANITIS LA
    QUETIAPINE - EFFICACY, SAFETY, AND TOLERABILITY IN ELDERLY SUBJECTS WITH PSYCHOTIC DISORDERS
    Psychopharmacology bulletin
    
    S.D. Targum e L.A. Arvanitis, "QUETIAPINE - EFFICACY, SAFETY, AND TOLERABILITY IN ELDERLY SUBJECTS WITH PSYCHOTIC DISORDERS", Psychopharmacology bulletin, 33(3), 1997, pp. 595-595
11. MCMANUS DQ; RAK IW; ARVANITIS LA
    SAFETY AND TOLERABILITY OF SEROQUEL(R)(QUETIAPINE) IN ELDERLY SUBJECTS WITH PSYCHOSIS
    Neurology
    
    D.Q. Mcmanus et al., "SAFETY AND TOLERABILITY OF SEROQUEL(R)(QUETIAPINE) IN ELDERLY SUBJECTS WITH PSYCHOSIS", Neurology, 48(3), 1997, pp. 2027-2027
12. ARVANITIS LA; MILLER BG; BORISON RL; PITTS WM; SHARIF ZA; HAMNER MB; HERZ MI; TRUE JE; VELLIGAN D; KNESEVICH MA; SMALL J; STEINBOOK R; HERTZMAN M; KECK PE; NEWCOMER JW; GRACE J; ROTROSEN J; TANDON R; DOTT SG; FERGUSON JM; ADDINGTON DEN; MACEWAN GW; NAIR VNP; SHRIQUI CL; WILLIAMS R; DANIEL DG; SHEHI GM; PATTERSON WM; MERIDETH CH
    MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO
    Biological psychiatry
    
    L.A. Arvanitis et al., "MULTIPLE FIXED DOSES OF SEROQUEL (QUETIAPINE) IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA - A COMPARISON WITH HALOPERIDOL AND PLACEBO", Biological psychiatry, 42(4), 1997, pp. 233-246
13. SMALL JG; HIRSCH SR; ARVANITIS LA; MILLER BG; LINK CGG; MURPHY AL; BOWDEN CL; OBRIEN CP; STEINBOOK RM; WAGNER RL; PITTS WM; CRABTREE B; CORRIGAN MHN; LOHR JB; MILLER AL; ERESHEFSKY L; ANDERSON CB; KNESEVICH MA; ROTROSEN J; OWEN RR; KARSON CN; LINDENMAYER JP; PFEFFERBAUM A; FAUSTMAN WO; KECK PE; PATTERSON WM; RIESENBERG RA; GLADSON MB; KOLIN IS; BARNES TRE; SENSKY T; RICCIO M; FRANKS S; JOLLEY A; HALLSTROM C; BENNIE E; DARCOURT G; PATRIS M; DESILVA M; PATEL AG; FLEISCHHACKER WW; DIETZEL M; SEIFERTOVA D; VINAR O; FALTUS F; BITTER I; OZSVATH K; SHAW SH; MAHAPATRA SN; SZULECKA TK; SUNDARARAJAN K; CREAVEN F; LYNCH J; KLIESER E; COOPER SJ; ASCHAUER H
    QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA - A HIGH-DOSE AND LOW-DOSE DOUBLE-BLIND COMPARISON WITH PLACEBO
    Archives of general psychiatry
    
    J.G. Small et al., "QUETIAPINE IN PATIENTS WITH SCHIZOPHRENIA - A HIGH-DOSE AND LOW-DOSE DOUBLE-BLIND COMPARISON WITH PLACEBO", Archives of general psychiatry, 54(6), 1997, pp. 549-557
14. BORISON RL; ARVANITIS LA; MILLER BG
    A COMPARISON OF 5 FIXED DOSES OF SEROQUEL (ICI-204,636) WITH HALOPERIDOL AND PLACEBO IN PATIENTS WITH SCHIZOPHRENIA
    Schizophrenia research
    
    R.L. Borison et al., "A COMPARISON OF 5 FIXED DOSES OF SEROQUEL (ICI-204,636) WITH HALOPERIDOL AND PLACEBO IN PATIENTS WITH SCHIZOPHRENIA", Schizophrenia research, 18(2-3), 1996, pp. 1-1
15. BORISON RL; ARVANITIS LA; MILLER BG; ALPHS LD; CARMAN JS; DIAMOND B; GEWIRTZ G; HAMNER MB; HIRSHFIELD R; MCEVOY JP; MUKHERJEE S; NASRALLAH HA; OXENKRUG G; RYAN W; SMITH N; TAMMINGA C
    ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC - EFFICACY AND SAFETY IN A MULTICENTER, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH SCHIZOPHRENIA
    Journal of clinical psychopharmacology
    
    R.L. Borison et al., "ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC - EFFICACY AND SAFETY IN A MULTICENTER, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH SCHIZOPHRENIA", Journal of clinical psychopharmacology, 16(2), 1996, pp. 158-169
16. ARVANITIS LA; MILLER BG
    ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC RESULTS FROM A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL
    Psychopharmacology bulletin
    
    L.A. Arvanitis e B.G. Miller, "ICI-204,636, AN ATYPICAL ANTIPSYCHOTIC RESULTS FROM A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL", Psychopharmacology bulletin, 32(3), 1996, pp. 391-391
17. HONG WW; ARVANITIS LA; MILLER BG; LINK CGG
    THE ATYPICAL PROFILE OF ICI-204,636 IS SUPPORTED BY ITS LACK OF INDUCTION OF EXTRAPYRAMIDAL SYMPTOMS
    Psychopharmacology bulletin
    
    W.W. Hong et al., "THE ATYPICAL PROFILE OF ICI-204,636 IS SUPPORTED BY ITS LACK OF INDUCTION OF EXTRAPYRAMIDAL SYMPTOMS", Psychopharmacology bulletin, 32(3), 1996, pp. 458-458
18. HAMNER MB; ARVANITIS LA; MILLER BG; LINK CGG; HONG WW
    PLASMA PROLACTIN IN SCHIZOPHRENIA SUBJECTS TREATED WITH SEROQUEL(TM) (ICI-204,636)
    Psychopharmacology bulletin
    
    M.B. Hamner et al., "PLASMA PROLACTIN IN SCHIZOPHRENIA SUBJECTS TREATED WITH SEROQUEL(TM) (ICI-204,636)", Psychopharmacology bulletin, 32(1), 1996, pp. 107-110
19. HIRSCH SR; LINK CGG; GOLDSTEIN JM; ARVANITIS LA
    ICI-204,636 - A NEW ATYPICAL ANTIPSYCHOTIC DRUG
    British Journal of Psychiatry
    
    S.R. Hirsch et al., "ICI-204,636 - A NEW ATYPICAL ANTIPSYCHOTIC DRUG", British Journal of Psychiatry, 168, 1996, pp. 45-56
20. BORISON RL; ARVANITIS LA; MILLER BG
    A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL WITH SEROQUEL - AN ATYPICAL ANTIPSYCHOTIC
    Biological psychiatry
    
    R.L. Borison et al., "A MULTIPLE FIXED-DOSE, PLACEBO-CONTROLLED TRIAL WITH SEROQUEL - AN ATYPICAL ANTIPSYCHOTIC", Biological psychiatry, 39(7), 1996, pp. 333-333
21. HONG WW; ARVANITIS LA; MILLER BG
    SEROQUEL (ICI-204,636) - NOT DIFFERENT FROM PLACEBO FOR EPS OF PROLACTIN
    Biological psychiatry
    
    W.W. Hong et al., "SEROQUEL (ICI-204,636) - NOT DIFFERENT FROM PLACEBO FOR EPS OF PROLACTIN", Biological psychiatry, 39(7), 1996, pp. 334-334
22. BORISON RL; ARVANITIS LA; MILLER BG; LINK CGG; HONG WW
    SEROQUEL (ICI-204,636) - A NOVEL, ATYPICAL ANTIPSYCHOTIC
    Biological psychiatry
    
    R.L. Borison et al., "SEROQUEL (ICI-204,636) - A NOVEL, ATYPICAL ANTIPSYCHOTIC", Biological psychiatry, 37(9), 1995, pp. 661-661
23. HAMNER MB; ARVANITIS LA; MILLER BG; LINK C; HONG WW
    THE EFFECTS OF SEROQUEL (ICI-204.636) ON PLASMA PROLACTIN IN PATIENTSWITH SCHIZOPHRENIA
    Biological psychiatry
    
    M.B. Hamner et al., "THE EFFECTS OF SEROQUEL (ICI-204.636) ON PLASMA PROLACTIN IN PATIENTSWITH SCHIZOPHRENIA", Biological psychiatry, 37(9), 1995, pp. 683-683